“…Complex interactions between genetic susceptibility to serotonergic and noradrenergic system dysfunction and stress-related changes in the HPA axis have been implicated in the etiology of depression (Firk, Markus, Firk, & Markus, 2007;Porter et al, 2004), and psychopharmacological treatment studies support the role of reduced neurotransmission of serotonin and norepinephrine in the pathophysiology of GAD (Nutt, Argyropoulos, Hood, & Potokar, 2006). Despite the extensive body of research linking corticotrophin-releasing factor and the HPA axis to depression (Hankin, Badanes, Abela, & Watamura, 2010;Nemeroff & Vale, 2005;Wardenaar, et al, 2011), almost 24 no research has investigated the role of the HPA axis in the etiology of GAD separate from the INT-FA anxiety disorders. Although findings of associations between the HPA axis functioning and anxiety disorders in general have been mixed (Risbrough & Stein, 2006), evidence from a study of HPA functioning in GAD patients showed significant changes in plasma cortisol following cognitive treatment (Tafet, Feder, Abulafia, & Roffman, 2005).…”